Novel Antischizophrenia Treatments

  • Mark A. Geyer
  • Gerhard Gross

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 213)

Table of contents

  1. Front Matter
    Pages i-x
  2. Richard S. E. Keefe, Philip D. Harvey
    Pages 11-37
  3. Jared W. Young, Nurith Amitai, Mark A. Geyer
    Pages 39-79
  4. Hsun-Hua Chou, Elizabeth Twamley, Neal R. Swerdlow
    Pages 81-111
  5. Colm M. P. O’Tuathaigh, Lieve Desbonnet, John L. Waddington
    Pages 113-145
  6. Sharon Rosenzweig-Lipson, Thomas A. Comery, Karen L. Marquis, Jonathan Gross, John Dunlop
    Pages 147-165
  7. David L. McKinzie, Frank P. Bymaster
    Pages 233-265
  8. Joseph T. Coyle, Alo Basu, Michael Benneyworth, Darrick Balu, Glenn Konopaske
    Pages 267-295
  9. E. J. Herman, M. Bubser, P. J. Conn, C. K. Jones
    Pages 297-365
  10. Anton Bespalov, Corinna Klein, Berthold Behl, Gerhard Gross, Hans Schoemaker
    Pages 419-442
  11. Back Matter
    Pages 443-455

About this book


This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.


Cognition Neurotransmitters Psychopharmacology Schizophrenia

Editors and affiliations

  • Mark A. Geyer
    • 1
  • Gerhard Gross
    • 2
  1. 1.Dept. PsychiatryUniversity of California San DiegoLa JollaUSA
  2. 2.Institut für Pharmakologie, Universität, Neuroscience ResearchAbbott GmbH & Co. KGLudwigshafenGermany

Bibliographic information